NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics announced today that it has been granted conditional approval for its fluorescence in situ hybridization (FISH)-based ROS1 lung cancer biomarker assay from the New York State Department of Health (NYSDOH).

With the decision, the company said its ROS1 FISH assay, which was acquired through Rosetta's purchase of PersonalizeDx earlier this year, is now available in all 50 US states.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Polygamy amplified a rare genetic disease in area near Arizona-Utah border, BBC Future reports.

Genetic ancestry testing led one woman to learn that her father and another baby boy had been switched at birth, the Washington Post reports.

Simple de-identification methods can protect information in a database from attackers, a new study suggests.

In Science this week: approach to visualize chromatin structure in nuclei, and more.